Novartis AG (NVSEF)
OTCMKTS
· Delayed Price · Currency is USD
110.14
+0.95 (0.87%)
May 13, 2025, 11:38 AM EDT
Novartis AG Revenue
Novartis AG had revenue of $13.62B in the quarter ending March 31, 2025, with 12.38% growth. This brings the company's revenue in the last twelve months to $53.22B, up 11.50% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
53.22B
Revenue Growth
+11.50%
P/S Ratio
4.01
Revenue / Employee
701.37K
Employees
75,883
Market Cap
213.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
Novartis AG News
- 21 hours ago - Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know - CNBC
- 1 day ago - Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet - Seeking Alpha
- 1 day ago - Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices - WSJ
- 1 day ago - Novartis to keep making malaria drugs if orders dry up amid aid cuts - Reuters
- 3 days ago - Pharma Worries Shift to Prices From Trade. Trump's Next Plan Could Sink Stocks. - Barrons
- 6 days ago - China sees global turmoil as opportunity to be ‘business friendly’, says Novartis chief - Financial Times
- 6 days ago - PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - Benzinga
- 7 days ago - BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion - Benzinga